Last updated on December 2018

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Peripheral T-Cell Lymphoma
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with a Japanese, Korean, Taiwanese, or Chinese ethnic background of each country/region
  • Patients aged 20 years on the date of informed consent
  • Patients with histologically confirmed diagnosis of one of the following:
  • Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
  • Angioimmunoblastic T-cell Lymphoma (AITL)
  • Anaplastic large cell lymphoma (ALCL), (ALK-positive/negative)
  • Relapsed or refractory patients with a treatment history of at least one regimen with antitumor agents for the above disease
  • Have at least 1 measurable lesion
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Patients with a life expectancy of at least 3 months as determined by the investigator

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.